insight review articles
The end of the beginning for
pluripotent stem cells
Peter J. Donovan* & John Gearhart†
*Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA (e-mail: pdonovan@lac.jci.tju.edu)
†The Institute of Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA (e-mail: gearhart@jhmi.edu)
Pluripotent stem cells can be expanded seemingly indefinitely in culture, maintain a normal karyotype and
have the potential to generate any cell type in the body. As such they represent an incredible resource for the
repair of diseased or damaged tissues in our bodies. These cells also promise to open a new window into the
embryonic development of our species.
T
he new millennium promised to usher in the era
of the human genome. So far, a different area of
biology — stem cell biology — has captured both
the scientific and international news headlines.
Stem cells are unique cells that have the capacity
for self-renewal and are capable of forming a least one, and
sometimes many, specialized cell types. Such stem cells are
present in many tissues of adult animals and are important in
tissue repair and homeostasis. For example, spermatogonial
stem cells in the testis are unipotent and produce only one
type of differentiated cell, a spermatozoon; whereas
haematopoietic stem cells are multipotent and produce erythrocytes and all the types of white blood cells. Pluripotent
stem cells can give rise theoretically to every cell type in the
animal body and are derived not from adult but rather from
embryonic tissues. Three types of mammalian pluripotent
stem cell lines have been isolated — embryonal carcinoma
(EC) cells, the stem cells of testicular tumours; embryonic
stem (ES) cells derived from pre-implantation embryos; and
embryonic germ (EG) cells derived from primordial germ
cells (PGCs) of the post-implantation embryo (Fig. 1).
If pluripotent stem cells derived from human embryos
behave like their counterparts from mice, they could be used
to treat a wide variety of human diseases, particularly those in
which specific cell types (such as cardiomyocytes, dopaminergic neurons and b-islet cells) have been lost or disabled. But
what is the reality? What are the important properties of
pluripotent stem cells and how do they differ from adult stem
cells? Do the results of studies in animal models suggest stem
cells can be used to correct disease phenotypes? How close are
we to taking stem cell-based treatments into the clinic? What
problems must be surmounted? Recent advances in
understanding the basic biology of pluripotent stem cells
suggest that they may be as useful as predicted, but major
hurdles remain to be overcome. Furthermore, the contribution that studies of these cells could have on understanding
the developmental biology of our own species has been
overshadowed by the hype surrounding the potential for
stem cell-based therapies. For the first time we can begin to
understand how cells of a human embryo grow and develop
to form a new individual and how that process can sometimes
go wrong. That opportunity comes with great responsibility,
but also inspires great awe.
The science of pluripotency
Defining pluripotent stem cell lines
As a distinct cell type, the pluripotent stem cell was first
recognized in teratocarcinomas. These are bizarre gonadal
92
tumours containing a wide array of tissues derived from the
three primary germ layers that make up an embryo: the
endoderm, mesoderm and ectoderm (refs 1,2, and see the
overview in this issue by Lovell-Badge, pages 88–91). These
tumours contain a large assortment of tissue types including
cartilage, squamous epithelia, primitive neuroectoderm,
ganglionic structures, muscle, bone and glandular epithelia.
The differentiated cells of the tumour are formed from
pluripotent EC cells present in the tumour, which themselves are derived from PGCs, the embryonic precursors of
the gametes3,4. EC cells are also one of the main components
of human testicular germ cell tumours and, as in the mouse,
evidence suggests that such tumours arise from PGCs5,
although this has not been proven formally6. Cultured EC
cell lines were derived by isolating EC cells from tumours
and growing them in medium containing serum either in
the presence or absence of a mitotically inactivated layer of
fibroblasts, termed a feeder layer7–9.
In contrast, ES cells are derived from the pluripotent
inner cell mass (ICM) cells of the pre-implantation, blastocyst-stage embryo10,11. Outgrowth cultures of blastocysts give
rise to different types of colonies of cells, some of which have
an undifferentiated phenotype. If these undifferentiated cells
are sub-cultured onto feeder layers they can be expanded to
form established ES cell lines that seem immortal.
And finally, EG cells are derived from cultured PGCs, the
same cells from which EC cells are derived12,13. PGCs isolated
directly from the embryonic gonad onto feeder layers will, in
the presence of serum and certain growth factors, form
colonies of cells that seem morphologically indistinguishable from EC cells or ES cells grown on feeder layers (Fig. 1).
Although EC, ES and EG cell lines have been isolated from
mice and humans14–16, only ES cells have been isolated from
non-human primates17,18.
The pluripotent stem cell lines have many attributes in
common, with some exceptions of uncertain significance
(Table 1). Some of the classical markers of these cells include
an isozyme of alkaline phosphatase, the POU-domain
transcription factor Oct4, high telomerase activity and a
variety of cell-surface markers recognized by monoclonal
antibodies to stage-specific embryonic antigens or to
tumour-recognition antigens19. Although some of these
markers are not unique to stem cells, they can nevertheless
serve as reagents with which to physically separate pluripotent stem cells from their differentiated derivatives. The
physiological significance of most of the markers is unclear,
with the exception of Oct4. Compelling studies carried out
in mouse EC, ES and EG cells, as well as in mouse embryos,
© 2001 Macmillan Magazines Ltd
NATURE | VOL 414 | 1 NOVEMBER 2001 | www.nature.com
insight review articles
Inner cell
mass
Fertilization
Figure 1 Origin of human pluripotent stem cells.
Embryonic stem (ES) cells are derived from the
inner cell mass of the pre-implantation embryo.
Embryonic germ (EG) cells are derived from
primordial germ cells (PGCs) isolated from the
embryonic gonad. Embryonal carcinoma (EC) cells
are derived from PGCs in the embryonic gonad but
usually are detected as components of testicular
tumours in the adult. All of the three pluripotent
stem cell types are usually derived by culture on
layers of mitotically inactive fibroblasts, termed
feeder layers.
Embryonic
stem cells
Teratocarcinoma
Embryonic germ cells
Embryonal carcinoma
Pluripotent
stem cells
point to a critical role for Oct4 in the establishment and/or maintenance of pluripotent cells in a pluripotent state20. Differentiation of
pluripotent cells is associated with downregulation of Oct4 levels,
and downregulation of the Oct4 gene in ES cells or in mice results in
the differentiation and loss of pluripotent cells21,22.
Developmental potential
The developmental potency of mouse pluripotent stem cells has been
tested in three independent assays: in vitro differentiation in a Petri
dish; differentiation into teratomas or teratocarcinomas when placed
in adult histocompatible or immunosuppressed mice; and in vivo
differentiation when introduced into the blastocoel cavity of a
pre-implantation embryo. All of the pluripotent stem cells can differentiate in vitro into a wide variety of cell types representative of the
three primary germ layers in the embryo (Fig. 2). When pluripotent
stem cells are introduced into histocompatible or immunocompromised mice, they form tumours that are indistinguishable from the
gonadal tumours from which EC cells were originally derived23,24. In
chimaeras, mouse ES and EG cells contribute to every cell type,
including the germline25–28. In contrast, murine EC cells introduced
into embryos colonize most embryonic lineages, but generally
do not colonize the germline, with one experimental exception29–32. The inability of EC cells to form functional gametes
most likely reflects their abnormal karyotype23,24. Because of
ethical concerns, non-human primate and human pluripotent
stem cells have not been tested for their ability to participate in
embryonic development in vivo, but in the other assays they behave
identically to their murine counterparts14–16.
The ability of pluripotent stem cells to give rise to a wide array of
differentiated derivatives is, of course, the reason why they may be so
useful for purposes of cell-based therapy. In the absence of factors
that inhibit their differentiation (see Box 1), pluripotent stem cell
differentiation has typically been directed by manipulating their
environment by trial and error. This can be achieved by growing stem
cells at high density, by growing them on different types of feeder
cells, by addition of growth factors, or by growth on crude or defined
extracellular matrix substrates (Fig. 2). In these conditions the types
NATURE | VOL 414 | 1 NOVEMBER 2001 | www.nature.com
Fetus
Blastocyst
Table 1 Comparisons among EC, ES and EG cells
EC
ES
EG
Derivation
PGC
ICM
PGC
Karyotype
Heteroploid
Euploid
Euploid
Chimaera formation
Soma
Soma & Germ
Soma & Germ
Alkaline phosphatase
+
+
+
Telomerase
+
+
+
Oct4
+
+
+
In vitro differentiation
+
+
+
EC/ES/EG cells
Oct4+, AP+, Telomerase+
- Feeders
Embryoid
bodies
Suspension
culture
-LIF
Figure 2 Differentiation of pluripotent stem cells into differentiated derivatives.
Cultured EC, ES and EG cells can be induced to differentiate into a wide variety of
differentiated derivatives in culture including pancreatic islet cells, blood cells, muscle
cells and nerve cells. Differentiation can be induced by withdrawal of leukaemia
inhibitory factor (LIF), separation of stem cells from feeder cells, or by growth of stem
cell colonies in suspension culture to form embryoid bodies, which upon dissociation
can be plated to yield differentiating cells.
© 2001 Macmillan Magazines Ltd
93
insight review articles
Box 1
Culture of pluripotent stem cells
An important property of pluripotent stem cells is their ability to divide
symmetrically in culture and give rise to two daughter cells that are
exact copies of the stem cell from which they were derived. This
property allows pluripotent stem cells to be expanded in culture
before induction of differentiation. Few of the factors that regulate
self-renewal of pluripotent stem cells are known. Typically, pluripotent
stem cell lines are isolated and maintained on mitotically inactive
feeder layers of fibroblasts. EC cells maintained on feeder layers
seem to retain developmental potency more readily than cells grown
without feeders66. Similar feeder-dependent culture conditions were
used for the isolation of mouse and human ES and EG cells and such
feeder layers proved critical to maintaining them in an undifferentiated
state10–16.
The requirement for feeder cells suggests that they provide a
factor that suppresses the differentiation or promotes the self-renewal
of pluripotent stem cells. An activity with these properties was
originally termed differentiation-inhibiting activity (DIA)67. DIA was
found to be the same as leukaemia inhibitory factor (LIF), a member of
the family of cytokines related to interleukin-6 (ref. 68).
For murine ES cells, LIF can replace the requirement for feeder
cells64. Importantly, activation of the signalling component of the LIF
receptor, glycoprotein 130 (gp130), is both necessary and sufficient
for inhibiting murine ES cell differentiation69. A crucial downstream
effector of gp130 is the signal transducer and activation of
of differentiated cell types formed can be varied and haphazard.
When grown in suspension, pluripotent stem cells will form embryoid bodies, structures originally described in teratomas and which
resemble the early pre-implantation embryo. In forming embryoid
bodies, stem cell differentiation may proceed in a way related to that
occurring in the embryo. Many differentiated cell types can be
derived, including neurons, glia, cardiomyocytes, skeletal myocytes,
adipocytes and haematopoietic cells. Differentiated cell types must
be sorted out from each other and away from stem cells. This can be
carried out by traditional methods of fluorescence activated cell sorting (FACS) if suitable cell-surface markers are available33, by selective
growth of differentiated cells if suitable culture conditions are
known34–36, or by introduction of a selectable marker that allows
either FACS separation of differentiated cells or drug selection to
ablate stem cells and other unwanted cells37 (Fig. 3).
The basic biology of human development
Although great attention has been given to the potential use of
human pluripotent stem cells in cell-based therapy, stem cells could
be equally important in dissecting the development of our own
species. Many of the in vitro techniques that have proven so useful for
analysing differentiation in murine ES cells can now be applied to
human cells. These include directed differentiation, gene trapping,
lineage marking, cell ablation and lineage selection24. In the not too
distant future we may be able to build a complete gene-expression
road map of how different cell types are formed, survive, proliferate,
differentiate and migrate during development. This information will
also help us to understand how embryogenesis can go wrong. The
effects of teratogens, agents that cause fetal malformations, could be
defined much more clearly than in the past and screening for new
teratogens could be facilitated38. Studies on the basic biology of
human pluripotent stem cells could also lay the fundamental
groundwork for future clinical applications.
Do we need stem cells from embryos?
Because pluripotent stem cells are able to form virtually any cell type
present in the body, many new disease treatments become possible.
94
transcription-3 (STAT3)70,71. Other signalling molecules acting
downstream of gp130, such as the mitogen-activated protein kinase,
seem to actually inhibit ES cell self-renewal72.
Isolation of human ES cells requires feeder cells (and 20% fetal
calf serum), but does not seem to require LIF14,16. However, human
ES cells grow on feeder cells that presumably produce multiple
growth factors. Therefore, it is possible that some of the same
downstream signalling molecules required for mouse ES cell
growth, including STAT3, are already activated in human ES cells
by other factors. The recent development of feeder-independent
culture conditions for human ES cells still necessitates the use of
(100%) conditioned medium from feeder cells65, indicating either
that these cells require factors produced by feeder cells or that
feeder cells remove some inhibitory factor from the culture
medium.
The isolation of EG cells from PGCs requires LIF and, in addition,
two other growth factors: Kit ligand (acting through the c-Kit
receptor) and basic fibroblast growth factor (bFGF or FGF2) (acting
through an FGF receptor)12,13. Once established, EG cells apparently
no longer require bFGF for their growth28. Both human and mouse
EG cells can be derived using the same combination of factors,
suggesting that some of the mechanisms regulating the
development of the germ line have been conserved during
mammalian evolution12,13,15.
In theory, neurons and glia could be produced to treat neurodegenerative diseases such as Parkinson’s and Alzheimer’s, muscle cells could
be produced to treat muscular dystrophies and heart disease,
haematopoietic stem cells could be produced to treat leukaemias and
AIDS. And the list goes on. But, pluripotent stem cells are derived
from discarded human embryos. For some in society this fact is an
insurmountable ethical problem. So why not use stem cells from
adults instead?
Adult stem cells were thought originally to have a limited
potential for production of differentiated derivatives. But recent
studies have questioned that view. These studies show, for example,
that neural stem cells can form blood-forming and muscle tissue39,
mesenchymal stem cells can produce differentiated cell types in the
brain40, and skin stem cells can make neurons, glia, smooth muscle
and adipocytes41. Such findings have had a significant impact on the
debate on the derivation and use of pluripotent stem cells derived
from embryos.
The main difference between embryo-derived pluripotent stem
cells and so-called multipotent stem cells from embryos or adult
animals is in the number of types of differentiated cells that can be
produced. This may reflect the different origins of the cells. Pluripotent stem cells are derived from germ cells or cells that can make germ
cells4,10–13. All other stem cells are derived from cells of the animal
body or soma (so-called somatic cells) that are no longer capable of
making germ cells. In adult animals it is only the germ cells that retain
the ability to make a new organism, a property known as developmental totipotency42,43. Although nuclear cloning experiments
demonstrate that the nuclei of somatic cells can be re-programmed
to allow them to become totipotent and recapitulate development44,45, in the normal life cycle of animal species they cannot and do
not do so. Despite several studies showing that many multipotent
stem cells are capable of forming a wider variety of cell types than
previously thought, it is unlikely that they can make the range of cell
types made by the embryo-derived pluripotent stem cells. Consequently, adult stem cells may be immensely useful for treatment of
some human diseases, but simply unable to make certain cell types
required for treatment of other diseases.
© 2001 Macmillan Magazines Ltd
NATURE | VOL 414 | 1 NOVEMBER 2001 | www.nature.com
insight review articles
Cell
sorting
Selective
growth
media
Selective
markers
HSCs
Muscle cells
Tissue
engineering
Single-cell
suspensions
Tissues or
organoids
cyte precursor cell, can be grown indefinitely in culture47. These
studies suggest that it might be possible to establish conditions in
which many adult multipotent stem cells can be grown indefinitely.
Nevertheless, the problems currently associated with expanding,
differentiating and genetically manipulating multipotent stem cells
impose certain constraints upon their use. These constraints might
preclude, for example, the use of patient-derived multipotent stem
cells for treating inherited disorders.
Much has been written on the relative merits of stem cells
obtained from embryonic, fetal and adult sources. Admittedly, it is
difficult at this time to appropriately compare stem cells from these
sources, as many of the claims have not appeared as peer-reviewed
publications. The most candid and realistic appraisal of these sources
has been published recently (11 September 2001) by the US National
Academy of Sciences. Until we are able to test stem cells from various
sources side by side in the laboratory in a variety of experimental
paradigms, we will not know unequivocally the ‘best’ source of stem
calls for a given therapy. Therefore, at the present time the weight of
evidence suggests there are good reasons to want to continue to work
with pluripotent stem cells derived from embryos and to vigorously
pursue their potential for treatment of human disease. The important question is what is really possible?
Bringing stem cells to the clinic
Successes in animal model studies
Transplantation
Figure 3 Isolation and separation of differentiated cells from pluripotent stem cells.
Differentiation of pluripotent stem cells occurs in a haphazard manner producing
many types of differentiated cell. Such differentiated cells can be isolated from other
cells, including stem cells, by fluorescence-activated cell sorting (FACS), by culture in
conditions that favour one cell type over another, or by the use of selectable markers
such as green fluorescent protein or resistance to neomycin. These selectable
markers must be expressed from a promoter construct that is introduced (by
electroporation or transfection) into the starting population of pluripotent stem cells
and that drives expression of the marker in the differentiated cell type of interest. Cells
can be transplanted as pure populations or, following tissue engineering, as tissues or
physiologically functional parts of organs (organoids).
Adult stem cells have other significant differences from pluripotent stem cells derived from embryos. These may reflect inherent
differences between the two cell types or simply technical problems
in growing adult stem cells. For example, in vitro culture conditions
have been established that allow pluripotent stem cells to be expanded seemingly indefinitely without losing differentiation potential,
and in which they maintain a normal chromosome number or
karyotype. In addition, murine ES and EG cells can be genetically
manipulated using the technique of homologous recombination,
and it seems likely that this technique could soon be applied to the
human cells. Similar conditions have not been established for most
adult stem cells. For example, adult haematopoietic stem cells,
defined as long-term repopulating cells, cannot be expanded in
culture without losing developmental potential46. But recent studies
show that one type of multipotent adult stem cell, the oligodendroNATURE | VOL 414 | 1 NOVEMBER 2001 | www.nature.com
So far, there have been few demonstrations that derivatives of stem
cells can be transplanted successfully in animal models of diseases or
injuries, but the demonstrations have been remarkable. Cardiomyocytes selected in culture from mouse ES cells could form stable,
apparently functioning intracardiac grafts in mice48. Mouse ES
cell-derived glial precursors, transplanted into a rat with myelin
disease, interact with the host neurons to produce myelin in the brain
and spinal cord49. Retinoic acid-treated embryoid bodies from
mouse ES cells, when transplanted into a rat spinal cord nine days
after traumatic injury, differentiated into astrocytes, oligodendrocytes and neurons, and promoted motor recovery50. A genetically
selected, insulin-producing cell line derived from mouse ES cells,
when implanted into the spleens of streptozotocin-induced diabetic
mice, result in normalized glycaemia51.
Initial results from studies using human pluripotent stem cells are
promising. In the first report using human pluripotent stem cell
derivatives in a transplantation paradigm, rats with a diffuse motor
neuron injury showed partial recovery of motor function (D. Kerr et
al., submitted). Neuronal cells derived from human EC cells after
treatment with retinoic acid have improved motor and cognitive
deficits in rats with stroke52,53 and are now being used in a safety trial
for patients with basal ganglia stroke54. Although the mechanisms for
improvements in the spinal cord and stroke studies remain to be
determined, the results are encouraging. The transplanted cells
could be substituting directly for lost populations of cells such as
neurons or glia, or they could be providing factors that facilitate the
regeneration of host cells.
The results of these few studies are consistent with the belief that
cell-based therapies from derivatives of pluripotent stem cells may
prove effective in ameliorating the effects of some devastating
diseases and injuries.
Stem cell expansion and differentiation
If stem cells are to be used to treat a wide variety of human diseases,
then we will need to overcome several formidable challenges. Stem
cells will be needed in large quantities and be able to differentiate in a
controlled manner to form homogeneous populations of cells that
are histocompatible with an individual.
How can stem cells be grown in large scale? Human stem cell
populations proliferate more slowly than their murine counterparts,
differentiate more readily and their cloning efficiency is very low14,55.
Recent studies show that addition of basic fibroblast growth factor
© 2001 Macmillan Magazines Ltd
95
insight review articles
inhibits their tendency to differentiate and at the same time improves
cloning efficiency56. But still conditions need to be improved. Efforts
to grow and manipulate mouse ES cells were aided by the availability
of multiple ES cell lines for which the right methods for growth and
subculture could be determined. Today a limited number of human
pluripotent stem cell lines exist throughout the world and only a few
pluripotent stem cell lines have been described in peer-reviewed
journals14–16,55. The number of usable cell lines is likely to be smaller
still. Some lines will be unavailable to many researchers because of
problems associated with material transfer agreements and patents.
Some cell lines may not survive in long-term culture and others that
do survive may do so by carrying gene mutations or chromosomal
alterations. Undoubtedly, the more cell lines available to work with
the more we will learn about their basic biology.
Some advances in defining the optimal conditions for growing
human pluripotent stem cells are likely to come from genomics.
Gene-expression analysis of stem cells using microarray technology
can provide key insights into the growth factors, growth-factor
receptors and cell-adhesion molecules produced by stem cells57,58.
This type of analysis should allow the biology of pluripotent stem
cells to be defined in a way that was unimaginable for the murine cells
some 20 years ago. The human genome sequence has now also provided a plethora of new growth factors in which to grow pluripotent
stem cells.
One approach to the problem of expansion of human pluripotent
stem cells is to differentiate them into other progenitor cells that are
easier to grow and expand16,59. Previous studies using mouse EC and
ES cells have shown that they can be induced to differentiate in
culture into embryoid bodies. Similar studies have now been carried
out with human pluripotent stem cells. Human embryoid bodies can
be used to derive cell lines that have the hallmarks of precursor or
progenitor cells, that can be expanded in culture, and that can
differentiate into a wide variety of derivatives, including neural cells,
vascular endothelium, muscle cells and endodermal derivatives59.
They also maintain a normal karyotype, can be cloned, cryopreserved and transfected. Differentiation of ES cells can also be induced
by growth at high density. In such conditions, neural progenitors can
be formed which themselves can be induced to form neurons16.
Production of expandable cell populations from pluripotent stem
cells overcomes some of the problems associated with growth of the
stem cells themselves.
Safety considerations in cell-based therapies
What are likely to be the problems associated with the use of stem cells
in the treatment of human diseases? As the gene therapy field has
learned, human disease treatment must be both safe and effective.
Three key safety issues are apparent. The first is whether cells can be
derived that are histocompatible with every individual. Because
human populations are genetically diverse, most types of transplantation have to overcome the problem of tissue rejection. Immune
suppression and tolerance induction are two possible solutions,
but both are short-term answers. Because stem cells are amenable
to genetic manipulation, there may be better ways to address the
problem.
Two methods can be used to generate embryo-derived pluripotent stem cells that are compatible with any individual. The first
method requires the creation of an embryo by isolating a somatic
nucleus from the patient and reprogramming it in an oocyte
cytoplasm — so-called therapeutic cloning or somatic cell nuclear
transfer. The embryo is then allowed to develop and stem cells are
derived from it that are genetically identical to the patient. The
second method requires that existing stem cell lines are genetically
modified by homologous recombination to create a stem cell that is
compatible with the patient. Presently both techniques are difficult
and remain significant hurdles to the use of pluripotent stem cells for
the treatment of disease phenotypes. Notably though, recent studies
have shown that human ES cells can be transfected, and undergo
96
drug selection and clonal expansion (albeit at low efficiency)56,55. So
three of the steps required for gene replacement or modification
through homologous recombination have been accomplished
successfully in human ES cells.
The second safety issue is whether transplanted pluripotent stem
cells will form tumours or otherwise differentiate improperly or
inappropriately after transplantation. The ability of EC, ES and EG
cells to form tumours in histocompatible animals reinforces the idea
that it might be advantageous to use differentiated cells rather than
stem cells for transplantation. Some studies suggest that imprinted
loci are erased in some EG cell lines, which could adversely affect their
growth characteristics60,61. But other studies show that many EG cells
behave normally in chimaeras13,26–28. Similarly, it has been reported
that murine ES cells show epigenetic instability and that animals
formed entirely from ES cells rarely survive62,63. But again, when ES
cells are introduced into embryos in the presence of other cells
(mirroring the proposed transplant situation) they differentiate into
apparently normal functional cells24.
Nevertheless, techniques need to be established for differentiating
human pluripotent stem cells homogeneously and for separating
them from stem cells, similar to those established for murine ES cells36.
These techniques will require the use of cell-surface markers (for
FACS separation of cells) and differential growth conditions (to inhibit stem cell growth or promote differentiated cell growth), together
with the introduction of selectable markers. The recent development
of techniques for transfecting human ES cells will certainly facilitate
the last method55. But if cells are introduced into specific sites, how can
we make sure that they migrate to the right sites and, perhaps more
important, make sure that they do not go to the wrong place. What
particular differentiation stage of cells should be used? These are some
of the fundamental questions that must be addressed experimentally
prior to bringing pluripotent stem cells to the clinic.
A third safety issue is associated with infectious agents that could
be present in embryo-derived pluripotent stem cells or acquired by
stem cells in feeder-dependent culture containing bovine serum.
Feeder-cell-independent culture conditions have been developed for
murine ES cells64 and more recently for human ES cells65. But the
human ES cells still require either fetal calf serum or conditioned
medium produced by mouse feeder cells for their growth65.
Ultimately it may be necessary to develop conditions for establishing
and growing pluripotent human stem cells in defined, serum-free
medium with purified recombinant growth factors and on defined
extracellular matrices.
An important question that still has to be addressed is what
criteria will be used by regulatory agencies (such as the Food and
Drug Administration in the United States) for cell-based therapies.
Will transplantation of single cell types be sufficient or will we need to
create tissues or ‘organoids’ for treatment of some diseases. It is likely
that many of these problems will be solved in non-human primate
models before moving to the clinic. It may be necessary to work out
grafting modalities for different cell types or for different tissue types
that are specific for each disease.
The future brings formidable challenges
Only time will tell whether the results of cell transplantation in animal models can be recapitulated in humans and whether it will prove
impossible to make certain cell types from pluripotent stem cells.
Without doubt the use of mouse ES cells has contributed enormously
to our understanding of the events of embryonic, fetal and postnatal
development as well as adult homeostasis in that organism and,
arguably, in mammals in general. Although the use of human
pluripotent stem cells could well spell a new era in human medicine,
such cells also promise to provide a unique window into the growth
and development of our own species. Like murine EC and ES cells
before them, human pluripotent stem cells can be used in in vitro
assays to dissect the mechanisms that guide early development.
Twenty years have passed since the isolation of mouse ES cells, an
© 2001 Macmillan Magazines Ltd
NATURE | VOL 414 | 1 NOVEMBER 2001 | www.nature.com
insight review articles
event that revolutionized the mouse as an experimental organism.
Now the availability of human pluripotent stem cells promises to
revolutionize our understanding of our own development and the
treatment of human disease. But there are still hurdles to be overcome
if human pluripotent stem cells are to be used to treat human disease.
On the road to the clinic we are not at the beginning of the end but,
perhaps, at the end of the beginning.
■
1. Stevens, L. C. The biology of teratomas. Adv. Morphogen. 6, 1–31 (1967).
2. Jiang, L. I. & Nadeau, J. H. 129/Sv mice—a model system for studying germ cell biology and testicular
cancer. Mammal. Genome 12, 89–94 (2001).
3. Kleinsmtih, L. J. & Pierce, G. B. Multipotentiality of single embryonal carcinoma cells. Cancer Res. 24,
1544–1552 (1964).
4. Stevens, L. C. Origin of testicular teratomas from primordial germ cells in mice. J. Natl Cancer Inst.
38, 549–552 (1967).
5. Skakkebaek, N. E., Berthelsen, J. G., Giwercman, A. & Muller, J. Carcinoma-in-situ of the testis:
possible origin from gonocytes and precursor of all types of germ cell tumours except
spermatocytoma. Int. J. Androl. 10, 19–28 (1987).
6. Andrews, P. W. Teratocarcinomas and human embryology: pluripotent human EC cell lines. Acta
Pathol. Microbiol. Immunol. Scand. 106, 158–167; discussion 167–168 (1998).
7. Kahan, B. W. & Ephrussi, B. Developmental potentialities of clonal in vitro cultures of mouse
testicular teratoma. J. Natl Cancer Inst. 44, 1015–1036 (1970).
8. Rosenthal, M. D., Wishnow, R. M. & Sato, G. H. In vitro growth and differentiation of clonal
populations of multipotential mouse cells derived from a transplantable testicular teratocarcinoma. J.
Natl Cancer Inst. 44, 1001–1014 (1970).
9. Evans, M. J. The isolation and properties of a clonal tissue culture strain of pluripotent mouse
teratoma cells. J. Embryol. Exp. Morphol. 28, 163–176 (1972).
10. Evans, M. J. & Kaufman, M. H. Establishment in culture of pluripotential cells from mouse embryos.
Nature 292, 154–156 (1981).
11. Martin, G. R. Isolation of a pluripotent cell line from early mouse embryos cultured in medium
conditioned by teratocarcinoma stem cells. Proc. Natl Acad. Sci. USA 78, 7634–7638 (1981).
12. Resnick, J. L., Bixler, L. S., Cheng, L. & Donovan, P. J. Long-term proliferation of mouse primordial
germ cells in culture. Nature 359, 550–551 (1992).
13. Matsui, Y., Zsebo, K. & Hogan, B. L. Derivation of pluripotential embryonic stem cells from murine
primordial germ cells in culture. Cell 70, 841–847 (1992).
14. Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282,
1145–1147 (1998).
15. Shamblott, M. J. et al. Derivation of pluripotent stem cells from cultured human primordial germ
cells. Proc. Natl Acad. Sci. USA 95, 13726–13731 (1998).
16. Reubinoff, B. E., Pera, M. F., Fong, C. Y., Trounson, A. & Bongso, A. Embryonic stem cell lines from
human blastocysts: somatic differentiation in vitro. Nature Biotechnol. 18, 399–404 (2000).
17. Thomson, J. A. et al. Isolation of a primate embryonic stem cell line. Proc. Natl Acad. Sci. USA 92,
7844–7848 (1995).
18. Thomson, J. A. et al. Pluripotent cell lines derived from common marmoset (Callithrix jacchus)
blastocysts. Biol. Reprod. 55, 254–259 (1996).
19. Pera, M. F., Reubinoff, B. & Trounson, A. Human embryonic stem cells. J. Cell Sci. 113, 5–10 (2000).
20. Pesce, M., Gross, M. K. & Scholer, H. R. In line with our ancestors: Oct-4 and the mammalian germ.
BioEssays 20, 722–732 (1998).
21. Nichols, J. et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU
transcription factor Oct4. Cell 95, 379–391 (1998).
22. Niwa, H., Miyazaki, J. & Smith, A. G. Quantitative expression of Oct-3/4 defines differentiation,
dedifferentiation or self-renewal of ES cells. Nature Genet. 24, 372–376 (2000).
23. Martin, G. R. Teratocarcinomas and mammalian embryogenesis. Science 209, 768–776 (1980).
24. Smith, A. in Stem Cell Biology 205–230 (Cold Spring Harbor Laboratory Press, 2001).
25. Bradley, A., Evans, M., Kaufman, M. H. & Robertson, E. Formation of germ-line chimaeras from
embryo-derived teratocarcinoma cell lines. Nature 309, 255–256 (1984).
26. Labosky, P. A., Barlow, D. P. & Hogan, B. L. Embryonic germ cell lines and their derivation from
mouse primordial germ cells. Ciba Found. Symp. 182, 157–168; discussion 168–178 (1994).
27. Labosky, P. A., Barlow, D. P. & Hogan, B. L. Mouse embryonic germ (EG) cell lines: transmission
through the germline and differences in the methylation imprint of insulin-like growth factor 2 receptor
(Igf2r) gene compared with embryonic stem (ES) cell lines. Development 120, 3197–3204 (1994).
28. Stewart, C. L., Gadi, I. & Bhatt, H. Stem cells from primordial germ cells can reenter the germ line.
Dev. Biol. 161, 626–628 (1994).
29. Brinster, R. L. The effect of cells transferred into the mouse blastocyst on subsequent development. J.
Exp. Med. 140, 1049–1056 (1974).
30. Illmensee, K. & Mintz, B. Totipotency and normal differentiation of single teratocarcinoma cells
cloned by injection into blastocysts. Proc. Natl Acad. Sci. USA 73, 549–553 (1976).
31. Papaioannou, V. E., Gardner, R. L., McBurney, M. W., Babinet, C. & Evans, M. J. Participation of
cultured teratocarcinoma cells in mouse embryogenesis. J. Embryol. Exp. Morphol. 44, 93–104 (1978).
32. Papaioannou, V. E., McBurney, M. W., Gardner, R. L. & Evans, M. J. Fate of teratocarcinoma cells
injected into early mouse embryos. Nature 258, 70–73 (1975).
33. Nishikawa, S. I., Nishikawa, S., Hirashima, M., Matsuyoshi, N. & Kodama, H. Progressive lineage
analysis by cell sorting and culture identifies FLK1+VE-cadherin+ cells at a diverging point of
endothelial and hemopoietic lineages. Development 125, 1747–1757 (1998).
34. Wiles, M. V. & Keller, G. Multiple hematopoietic lineages develop from embryonic stem (ES) cells in
culture. Development 111, 259–267 (1991).
35. Nakano, T., Kodama, H. & Honjo, T. Generation of lymphohematopoietic cells from embryonic stem
cells in culture. Science 265, 1098–1101 (1994).
36. Li, M., Pevny, L., Lovell-Badge, R. & Smith, A. Generation of purified neural precursors from
NATURE | VOL 414 | 1 NOVEMBER 2001 | www.nature.com
embryonic stem cells by lineage selection. Curr. Biol. 8, 971–974 (1998).
37. Muller, M. et al. Selection of ventricular-like cardiomyocytes from ES cells in vitro. FASEB J. 14,
2540–2548 (2000).
38. Eiges, R. et al. Establishment of human embryonic stem cell-transfected clones carrying a marker for
undifferentiated cells. Curr. Biol. 11, 514–518 (2001).
39. Bjornson, C. R., Rietze, R. L., Reynolds, B. A., Magli, M. C. & Vescovi, A. L. Turning brain into blood:
a hematopoietic fate adopted by adult neural stem cells in vivo. Science 283, 534–537 (1999).
40. Mezey, E., Chandross, K. J., Harta, G., Maki, R. A. & McKercher, S. R. Turning blood into brain: cells
bearing neuronal antigens generated in vivo from bone marrow. Science 290, 1779–1782 (2000).
41. Toma, J. et al. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nature
Cell Biol. 3, 778–784 (2001).
42. McLaren, A. Mammalian germ cells: birth, sex, and immortality. Cell Struct. Funct. 26, 119–122 (2001).
43. Pesce, M. & Scholer, H. R. Oct-4: control of totipotency and germline determination. Mol. Reprod.
Dev. 55, 452–457 (2000).
44. Campbell, K. H., McWhir, J., Ritchie, W. A. & Wilmut, I. Sheep cloned by nuclear transfer from a
cultured cell line. Nature 380, 64–66 (1996).
45. Wakayama, T., Perry, A. C., Zuccotti, M., Johnson, K. R. & Yanagimachi, R. Full-term development of
mice from enucleated oocytes injected with cumulus cell nuclei. Nature 394, 369–374 (1998).
46. Weissman, I. L. Translating stem and progenitor cell biology to the clinic: barriers and opportunities.
Science 287, 1442–1446 (2000).
47. Tang, D. G., Tokumoto, Y. M., Apperly, J. A., Lloyd, A. C. & Raff, M. C. Lack of replicative senescence
in cultured rat oligodendrocyte precursor cells. Science 291, 868–871 (2001).
48. Klug, M. G., Soonpaa, M. H., Koh, G. Y. & Field, L. J. Genetically selected cardiomyocytes from
differentiating embryonic stem cells form stable intracardiac grafts. J. Clin. Invest. 98, 216–224 (1996).
49. Brustle, O. et al. Embryonic stem cell-derived glial precursors: a source of myelinating transplants.
Science 285, 754–756 (1999).
50. McDonald, J. W. et al. Transplanted embryonic stem cells survive, differentiate and promote recovery
in injured rat spinal cord. Nature Med. 5, 1410–1412 (1999).
51. Soria, B. et al. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in
streptozotocin-induced diabetic mice. Diabetes 49, 157–162 (2000).
52. Borlongan, C. V., Tajima, Y., Trojanowski, J. Q., Lee, V. M. & Sanberg, P. R. Cerebral ischemia and
CNS transplantation: differential effects of grafted fetal rat striatal cells and human neurons derived
from a clonal cell line. NeuroReport 9, 3703–3709 (1998).
53. Muir, J. K. et al. Terminally differentiated human neurons survive and integrate following
transplantation into the traumatically injured rat brain. J. Neurotrauma 16, 403–414 (1999).
54. Kondziolka, D. et al. Transplantation of cultured human neuronal cells for patients with stroke.
Neurology 55, 565–569 (2000).
55. Scholz, G., Pohl, I., Genschow, E., Klemm, M. & Spielmann, H. Embryotoxicity screening using
embryonic stem cells in vitro: correlation to in vivo teratogenicity. Cells Tiss. Organs 165, 203–211
(1999).
56. Amit, M. et al. Clonally derived human embryonic stem cell lines maintain pluripotency and
proliferative potential for prolonged periods of culture. Dev. Biol. 227, 271–278 (2000).
57. Phillips, R. L. et al. The genetic program of hematopoietic stem cells. Science 288, 1635–1640 (2000).
58. Terskikh, A. V. et al. From hematopoiesis to neuropoiesis: evidence of overlapping genetic programs.
Proc. Natl Acad. Sci. USA 98, 7934–7939 (2001).
59. Shamblott, M. J. et al. Human embryonic germ cell derivatives express a broad range of
developmentally distinct markers and proliferate extensively in vitro. Proc. Natl Acad. Sci. USA 98,
113–118 (2001).
60. Tada, M., Tada, T., Lefebvre, L., Barton, S. C. & Surani, M. A. Embryonic germ cells induce epigenetic
reprogramming of somatic nucleus in hybrid cells. EMBO J. 16, 6510–6520 (1997).
61. Tada, T. et al. Epigenotype switching of imprintable loci in embryonic germ cells. Dev. Genes Evol.
207, 551–561 (1998).
62. Humpherys, D. et al. Epigenetic instability in ES cells and cloned mice. Science 293, 95–97 (2001).
63. Nagy, A., Rossant, J., Nagy, R., Abramow-Newerly, W. & Roder, J. C. Derivation of completely cell
culture-derived mice from early-passage embryonic stem cells. Proc. Natl Acad. Sci. USA 90,
8424–8428 (1993).
64. Nichols, J., Evans, E. P. & Smith, A. G. Establishment of germ-line-competent embryonic stem (ES)
cells using differentiation inhibiting activity. Development 110, 1341–1348 (1990).
65. Xu, C. et al. Feeder-free growth of undifferentiated human embryonic stem cells. Nature Biotechnol.
19, 971–974 (2001).
66. Martin, G. R. & Evans, M. J. Differentiation of clonal lines of teratocarcinoma cells: formation of
embryoid bodies in vitro. Proc. Natl Acad. Sci. USA 72, 1441–1445 (1975).
67. Smith, A. G. et al. Inhibition of pluripotential embryonic stem cell differentiation by purified
polypeptides. Nature 336, 688–690 (1988).
68. Williams, R. L. et al. Myeloid leukaemia inhibitory factor maintains the developmental potential of
embryonic stem cells. Nature 336, 684–687 (1988).
69. Yoshida, K. et al. Maintenance of the pluripotential phenotype of embryonic stem cells through direct
activation of gp130 signalling pathways. Mech. Dev. 45, 163–171 (1994).
70. Niwa, H., Burdon, T., Chambers, I. & Smith, A. Self-renewal of pluripotent embryonic stem cells is
mediated via activation of STAT3. Genes Dev. 12, 2048–2060 (1998).
71. Matsuda, T. et al. STAT3 activation is sufficient to maintain an undifferentiated state of mouse
embryonic stem cells. EMBO J. 18, 4261–4269 (1999).
72. Burdon, T., Stracey, C., Chambers, I., Nichols, J. & Smith, A. Suppression of SHP-2 and ERK
signalling promotes self-renewal of mouse embryonic stem cells. Dev. Biol. 210, 30–43 (1999).
Acknowledgements
We apologize to the colleagues whose work was not cited because of space constraints. We
are indebted to L. F. Lock for critical comments on the manuscript and with L. Cheng, D.
Panchision, H. Scholer, M. Bartolomei, L. Iacovitti and J. McLaughlin for helpful
discussions. We thank M. Linkinhoker for help with the figures.
© 2001 Macmillan Magazines Ltd
97